(Check out Carter’s worthcharting.com for actionable recommendations and live nightly videos.) Mid-cap biotech Immunovant is judged to be setup especially well for a move higher, by our work. In the throes of a “bearish-to-bullish” reversal, the stock exhibits bullish price-volume correlation and impressive relative strength to the market and to other biotechnology stocks. We’re buyers here. Price Objective: $40+/- This pair of identical charts of Immunovant tell the story: Source: FactSet DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, or its parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL’S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
Trending
- Spirit Airlines’ collapse, high gas prices, airfares test limits of summer vacation spending
- Comptroller Issues Statement Explaining Abstention from FDIC Vote on Resolution Plan Feedback
- Bitcoin’s hard-money thesis is colliding with 5% Treasury yields
- Better Financial Sector ETF: Vanguard’s VFH vs. State Street’s XLF
- Anyone Saying That AI Is Not Replacing Jobs, Is Lying
- World’s Most Fervent Day Traders in Korea to Get Risky New Tools
- The Next Stock That Could Surge by 1000%?
- Restaurants Navigate Higher Food Costs as Burger Season Begins
Sunday, May 24
